YaBing Guo - Nanfang Hospital, First Military Medical University

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 154 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Transarterial Chemoembolisation Combined with Lenvatinib Plus Pembrolizumab Versus Dual Placebo for Unresectable, Non-Metastatic Hepatocellular Carcinoma (LEAP-012): a Multicentre, Randomised, Double-Blind, Phase 3 Study

Masatoshi Kudo,Zhenggang Ren,Yabing Guo,Guohong Han, Hailan Lin,Jinfang Zheng,Sadahisa Ogasawara,Ji Hoon Kim,Haitao Zhao,Chuan Li,David C. Madoff,R. Mark Ghobrial,Tomokazu Kawaoka,Masafumi Ikeda, Rene Gerolami,Hiromitsu Kumada,Anthony B. El-Khoueiry,Arndt Vogel, Xiang Peng,Kalgi Mody,Corina Dutcus,Leonid Dubrovsky,Abby B. Siegel,Richard S. Finn, Josep M. Llovet

LANCETno. 10474 (2025): 203-215

Cited1Views0WOSBibtex

Toripalimab Plus Bevacizumab Versus Sorafenib As First-Line Treatment for Advanced Hepatocellular Carcinoma (HEPATORCH): a Randomised, Open-Label, Phase 3 Trial

Yinghong Shi,Guohong Han,Jian Zhou,Xuetao Shi,Weidong Jia,Ying Cheng, Yongdong Jin, Xiangdong Hua,Tianfu Wen,Jianbing Wu,Shanzhi Gu,Yuxian Bai,Xiangcai Wang,Tao Zhang,Zhiyu Chen,Bixiang Zhang, Ming Huang,Hongming Liu,Yilei Mao,Ledu Zhou, Rui Wang,Yunfeng Shan,Wu Zhang,Tianqiang Song,Yabing Guo,Fuxiang Zhou,Bingfeng Shao,Mingjun Zhang, Bo Liang,Jinfang Zheng, Guoping Zhang,Jie Shen,Weiwen Su, Feng Zhang,Yifu He,Sheng Hu,Rong Liu,Chengwu Zhang,Shunli Shen,Hui Zeng, Tsang-En Wang,Wenzhi Guo,Yan Shen,Yajin Chen,Yong Li, J Samol,Hongtao Hu, Wenhua Zhang,Chengyou Du,Enxiao Li,Chao Liu,Choo Su Pin,Xun Li,Hao Xu, Jee-Fu Huang,Chunyi Hao,Jing Lv, Wei Wang, Qian Xu, Aobing Bai,Xiao Zhang, Bifeng Liu, Chunlei Jin,Jia Fan

The lancet Gastroenterology & hepatologyno. 7 (2025): 658-670

Cited0Views0WOSBibtex

Porustobart (HBM4003) Plus Toripalimab As Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: a Multicenter, Open-Label, Phase I Study

Ningning Zhang, Tian Liu, Ming Luo,Jihui Hao,Shukui Qin,Yanqiao Zhang, Gang Wang,Yajin Chen,Jingdong Zhang,Shanzhi Gu,Junqi Niu,Guijie Xin,Ge Yu,Yabing Guo, Chongyuan Xu,Jun Yao,Jie Shen, Aibing Xu, Shuwen Zhang, Di Yang, Meijuan Gao, Ruixuan Luo, Yebo He, Fei Zheng, Nan Cao, Xiaolu Tao

Clinical cancer research an official journal of the American Association for Cancer Research (2025)

Cited0Views0WOSBibtex

First-line Iparomlimab and Tuvonralimab (QL1706) or Iparomlimab (QL1604) + Bevacizumab (BEV) for Unresectable Hepatocellular Carcinoma (HCC): Updated Results from the Phase Ib/II DUBHE-H-106 Study

Feng Bi,Yanqiao Zhang,Yabing Guo,Zhongyuan Xu,Shanzhi Gu, Yao Huang,Mingxu Da, Zhiyu Chen,Chaoying Liu,Yaozhen Pan, Hao Ying, Ming Huang,Zheng Wang,Jianbing Wu,Jun Zhao, Ranran Sun,Shujun Yang, Xiaokui Yu, Hui Li,Shilin Xue

Journal of Clinical Oncologyno. 4_suppl (2025): 579-579

Cited0Views0Bibtex

Camrelizumab Plus Rivoceranib Vs Sorafenib As First-Line Therapy for Unresectable Hepatocellular Carcinoma (uhcc): Final Overall Survival Analysis of the Phase 3 CARES-310 Study

Arndt Vogel,Stephen Lam Chan,Zhenggang Ren,Yuxian Bai,Shanzhi Gu,Xiaoyan Lin,Zhendong Chen,Weidong Jia,Yongdong Jin,Yabing Guo,Xiaohua Hu,Alexander Valerievich Sultanbaev,Monika Pazgan-Simon, Margaryta Pisetska, Tsz Keung Nip, Haisong Zhang, Jinghua Du,Ann-Lii Cheng,Ahmed Omar Kaseb,Shukui Qin

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study

Jianping Xiong,Weiwei Ouyang,Mengxiang Yang,Zhenyuan Gao,Huan Zhou,Hanmei Lou,Yabing Guo,Zhongyuan Xu,Ling Zheng,Ying Liu,Zhongfeng Wang,Ping Sun,Huerxidan Niyazi, Jianhua Wang, Yan Chen,Baihui Zhang,Lingyan Li,Xiaoyan Kang,Weijian Guo

Advances in Therapypp.1-19, (2024)

Cited0Views0WOSBibtex

Evaluation of an Artificial Intelligence-Based Clinical Trial Matching System in Chinese Patients with Hepatocellular Carcinoma: A Retrospective Study

Kunyuan Wang,Hao Cui,Yun Zhu,Xiaoyun Hu,Chang Hong,Yabing Guo, Lingyao An,Qi Zhang,Li Liu

BMC Cancer（2024）

Cited0Views0WOSBibtex

Abstract CT150: Result of an Open-Label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor Onatasertib (ATG-008) in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

Shukui Qin,Xiaoyan Lin, Zhiqaing Meng,Zhenggang Ren,Yuxian Bai,Shanzhi Gu,Li Zheng,Qiu Li, Sun-Yong Oh,Yabing Guo, Yoong-Koo Kang,Wei-Yu Kao,Wei Li,Jung-Hwan Yoon,Helong Zhang,Pei-Jer Chen,Tsai-Sheng Yang,Jeong Heo,Zhendong Zheng, Hui Xie, Zhinuan Yu

Cancer Researchno. 8_Supplement (2023)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

YaBing Guo(郭亚兵)

Papers共 154 篇Author StatisticsCo-AuthorSimilar Experts